ACSL4 and hepatocellular carcinoma: Together, these results suggest that ETS1-dependant miR-23a-3p upregulation leads to sorafenib resistance by inhibiting ferroptosis via suppression of ACSL4 axis, highlighting targeting miR-23a-3p as a potential target to overcome resistance to sorafenib in HCC patients.